Bionano Genomics (BNGO) presents a deeply negative liquidation posture as of December 31, 2025. Total assets are $73.6M against total liabilities of $29.2M, yielding GAAP book equity of approximately $44.4M. Under liquidation haircuts, recoverable asset value is materially lower. Cash and cash equivalents of $3.0M recovers at 100%; restricted cash brings total cash-equivalent recoverable to approximately $4.5M. Short-term investments (available-for-sale debt securities) of $16.3M are near par and recover close to face value. Accounts receivable net of $5.2M recovers at 90-95% (~$4.7-4.9M). Inventory of $7.8M current plus $2.4M noncurrent ($10.2M gross) applies a 60% recovery haircut (~$6.1M). PP&E net book value is not separately tagged but can be inferred from accumulated depreciation of $28.2M against gross; the company reported $7.2M D&A for 2025 suggesting significant asset consumption. Intangibles net of $4.3M and finite-lived intangibles net of $4.2M receive 0% liquidation recovery. ROU assets (operating $3.2M, finance $3.1M) recover near zero in liquidation. Operating lease liabilities of $3.2M and finance lease liabilities of $3.7M remain at full face value on the liability side and do not extinguish on wind-up. The MFFAIS CLV of -$25.9M and LLV of -$20.7M confirm negative equity recovery to common shareholders under liquidation. The company's $26.4M net loss for 2025 is a significant improvement from the prior year's $104M+ operating loss (2024 operating loss $104.0M vs. 2025 operating loss $33.3M), reflecting aggressive cost restructuring that cut total operating expenses from $104.4M to $46.5M YoY, primarily via headcount reduction (salaries $51.1M to $24.4M) and contracted services ($18.9M to $9.3M). However, revenue also declined from $30.8M to $28.5M, and the company remains cash-burning at $16.3M from operations. As of year-end, cash of $3.0M is minimal; the company raised $31.1M gross from equity issuances during 2025 (September 2025 offering) and holds $16.3M in short-term investments, providing near-term liquidity but no path to positive liquidation recovery to equity. The deferred tax asset valuation allowance of $146.5M (up from $140.5M) and $531M in federal NOL carryforwards have zero liquidation value. Filing discusses the OBBBA enacted July 2025 in MD&A/footnotes but its impact on deferred tax assets is moot given full valuation allowance. The board has explored strategic alternatives; the prior 10-Q filing (Q3 2025) explicitly discusses dissolution risk if no strategic transaction is consummated, which is material context for the liquidation lens.
▼ Community Notes